188 related articles for article (PubMed ID: 37305839)
21. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
[TBL] [Abstract][Full Text] [Related]
22. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
[TBL] [Abstract][Full Text] [Related]
23. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ
Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
[TBL] [Abstract][Full Text] [Related]
24. Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin.
Volpicelli L; Venditti M; Oliva A
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):329-341. PubMed ID: 36803139
[TBL] [Abstract][Full Text] [Related]
25. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
[TBL] [Abstract][Full Text] [Related]
26. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
[TBL] [Abstract][Full Text] [Related]
27. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
Juul JJ; Mullins CF; Peppard WJ; Huang AM
Ther Clin Risk Manag; 2016; 12():225-32. PubMed ID: 26937194
[TBL] [Abstract][Full Text] [Related]
28. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
29. Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience.
Scarano SM; Bruzzese E; Poeta M; Del Bene M; Guarino A; Lo Vecchio A
Antibiotics (Basel); 2024 Apr; 13(4):. PubMed ID: 38667003
[TBL] [Abstract][Full Text] [Related]
30. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
31. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
Smith JR; Roberts KD; Rybak MJ
Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
[TBL] [Abstract][Full Text] [Related]
33. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Soriano A; Rossolini GM; Pea F
Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
[No Abstract] [Full Text] [Related]
34. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
[TBL] [Abstract][Full Text] [Related]
35. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
Jame W; Basgut B; Abdi A
PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections.
Wang Y; Wang J; Wang R; Li Y; Cai Y
J Glob Antimicrob Resist; 2021 Mar; 24():72-80. PubMed ID: 33279683
[TBL] [Abstract][Full Text] [Related]
38. Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Gonzalez J; Andrade DC; Niu J
Clin Infect Dis; 2021 Oct; 73(7):e1436-e1442. PubMed ID: 33211794
[TBL] [Abstract][Full Text] [Related]
39. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
40. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
